MARGINAL ZONE LYMPHOMA (MZL)
Clinical trials for MARGINAL ZONE LYMPHOMA (MZL) explained in plain language.
Never miss a new study
Get alerted when new MARGINAL ZONE LYMPHOMA (MZL) trials appear
Sign up with your email to follow new studies for MARGINAL ZONE LYMPHOMA (MZL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.
Matched conditions: MARGINAL ZONE LYMPHOMA (MZL)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo therapy aims to wipe out lymphoma without prior treatment
Disease control OngoingThis study tests a combination of three drugs (orelabrutinib, zuberitamab, and chemotherapy) in 65 adults with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the treatment can make all signs of cancer disappear for at least 24 months. Partici…
Matched conditions: MARGINAL ZONE LYMPHOMA (MZL)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for eye cancer: targeted drug combo shows promise in early trial
Disease control OngoingThis phase II trial tests a targeted cancer drug called orelabrutinib combined with either low-dose radiation or another drug (rituximab) in 39 people with a rare eye lymphoma (ocular adnexal MALT lymphoma). The goal is to see how well the combination shrinks tumors and how safe …
Matched conditions: MARGINAL ZONE LYMPHOMA (MZL)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Is 'Watch and Wait' really 'Worry and Wait'? new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how the 'watch and wait' approach affects the quality of life of people with slow-growing lymphomas like CLL and follicular lymphoma. Researchers will ask 250 Korean patients to fill out questionnaires about their well-being and anxiety. The goal is to underst…
Matched conditions: MARGINAL ZONE LYMPHOMA (MZL)
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC